| Author | Aguiar, Marta Gontijo de | |
| Author | Gonçalves, José Eduardo | |
| Author | Souza, Mirna d'Auriol | |
| Author | Silva, Rosiana Estefáne de | |
| Author | Silveira, Josianne Nicacio | |
| Author | Cota, Gláucia Fernandes | |
| Access date | 2022-10-07T16:21:21Z | |
| Available date | 2022-10-07T16:21:21Z | |
| Document date | 2018 | |
| Citation | AGUIAR, Marta Gontijo de et al. Plasma antimony determination during cutaneous leishmaniasis treatment with intralesional infiltration of meglumine antimoniate. Trop Med Int Health., v. 23, n. 10, p. 1110-1117, 2018. doi: 10.1111/tmi.13130. | en_US |
| ISSN | 1360-2276 | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/55052 | |
| Sponsorship | CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO | en_US |
| Language | eng | en_US |
| Publisher | Blackwell Science Ltd | en_US |
| Rights | restricted access | |
| Title | Plasma antimony determination during cutaneous leishmaniasis treatment with intralesional infiltration of meglumine antimoniate | en_US |
| Type | Article | |
| DOI | 10.1111/tmi.13130 | |
| Abstract | ObjectivesTo evaluate the antimony (Sb) in plasma of patients who underwent a standardised meglumine antimoniate (MA) intralesional infiltration protocol for cutaneous leishmaniasis treatment.
MethodsThe level of Sb in plasma was determined by atomic absorption spectroscopy, before and 1, 2, 4 and 6 hours after the first intralesional infiltration of MA to determine the parameters peak concentrations (C-1 h)(,) area under curve of drug concentration in plasma from zero to 6 h (AUC(0-6 h)) and elimination half-life (t1/2) of Sb. Blood samples were also collected weekly during the treatment period, always before infiltration.
ResultsFourteen patients underwent MA intralesional infiltration with doses ranging from 0.8 to 9 mg Sb/kg at the first infiltration. The C-1 h ranged from 3850 to 47 095 mg x h/L and was the highest concentration obtained for 11 of 14 patients after the first intralesional infiltration of MA. A rapid initial phase of distribution lasting up to 4 h (2.6 0.34 h) was followed by a slower elimination phase. Total skin lesion area, C-1 h and AUC((0-6 h)) were related to the dose of Sb infiltered (P < 0.05). Plasma Sb in samples collected weekly before the infiltration revealed antimony concentrations below the quantification limit (15.0 g Sb/l) during the treatment period.
ConclusionsSb is quickly absorbed and eliminated after intralesional administration of MA, in a pattern similar to that reported with the Sb systemic administration. Using a therapeutic schedule limited to weekly intralesional infiltration of doses <10 mg Sb/kg does not result in plasma Sb accumulation. | en_US |
| Affilliation | Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Produtos Farmacêuticos. Belo Horizonte, MG, Brazil | en_US |
| Affilliation | Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Produtos Farmacêuticos. Belo Horizonte, MG, Brazil | en_US |
| Affilliation | Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Análises Clínicas e Toxicológicas. Belo Horizonte, MG, Brazil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Centro de Referência em Leishmanioses. Belo Horizonte, MG, Brazil/Fundação Oswaldo Cruz. Instituto René Rachou. Pesquisa Clínica e Políticas Públicas em Doenças Infecto-Parasitárias. Belo Horizonte, MG, Brazil | en_US |
| Affilliation | Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Análises Clínicas e Toxicológicas. Belo Horizonte, MG, Brazil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto René Rachou. Centro de Referência em Leishmanioses. Belo Horizonte, MG, Brazil/Fundação Oswaldo Cruz. Instituto René Rachou. Pesquisa Clínica e Políticas Públicas em Doenças Infecto-Parasitárias. Belo Horizonte, MG, Brazil | en_US |
| Subject | antimoine | en_US |
| Subject | antimoniate de méglumine | en_US |
| Subject | cutaneous leishmaniasis | en_US |
| Subject | intralesional therapy | en_US |
